Editor´s Pick

      Editor´s Pick

      Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

      PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission has approved Sotyktu (deucravacitinib), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor,...
      Admin -
      Editor´s Pick

      Over One-Third of Americans Are Not Taking Prescribed Medication Due to Financial Difficulties

      The financial burden of prescription medications is a growing concern for many Americans. According to a recent survey, over one-third of Americans are not...
      Admin -
      Editor´s Pick

      Newel Health Receives $2.5M Grant from The Michael J. Fox Foundation to Advance Soturi, a Digital Therapeutic for Parkinson’s Disease.

      Newel Health, a digital health company, recently announced that it has received a $2.5 million grant from The Michael J. Fox Foundation (MJFF) to...
      Admin -
      Editor´s Pick

      Amazon Launches RxPass Subscription Service for Prime Members: Unlimited Prescription Medications Delivered Free for $5/Month.

      Amazon recently announced the launch of its new RxPass subscription service for Prime members. The service offers unlimited prescription medications delivered free for just...
      Admin -
      Editor´s Pick

      Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

      NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) granted...
      Admin -
      Editor´s Pick

      European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations

      FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has authorized a new low-dose tablet dosage form of...
      Admin -
      123...8Page 1 of 8

      Recent Articles

      Cytonus expands its Scientific Advisory Board with mRNA expert Michael Houston, PhD

      Look Who’s On the Move!

      Switch Therapeutics Expands Leadership Team with Key Appointments

      Industry News

      CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment

      Industry News

      Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics Division

      Look Who’s On the Move!

      Newron Presents Six-Month Interim Data From the First 100 Patients Randomized in Study 014/015 at the 31st European Congress of Psychiatry

      Industry News

      Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

      Editor´s Pick

      Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development

      Look Who’s On the Move!

      Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases

      Industry News

      Prilenia Achieves Last Patient Last Visit in Phase 3 PROOF-HD Clinical Study for Huntington’s Disease

      Industry News

      Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology

      Industry News

      Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors

      Look Who’s On the Move!

      Andrew Miller Joins Elucid as Chief Technology Officer

      Look Who’s On the Move!

      OncoVerity, Inc. Announces Exclusive Worldwide Licensing Rights to Cusatuzumab and Appoints Max Colao as Chief Executive Officer

      Regulatory Affairs

      ANANDA Scientific Announces First Patient Enrolled in FDA-approved Clinical Trial Evaluating a Potential New Treatment for Social Anxiety Disorder (SAD)

      Regulatory Affairs

      Direct Biologics Announces First Patient Dosed with ExoFlo™ in a Phase 1 Clinical Trial for Medically Refractory Ulcerative Colitis

      Industry News

      2021 © Copyright - TPMG

      Get a free copy of "Cracking the Generics Code"

      Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.